CellaVision Receives First Order from China

CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has via its Chinese distributor Vastec Medical Ltd officially been approved for sale of its analyzers in China. In connection to this, Vastec Medical has received its first order from Xijing Hospital in Xi'an.

"China is an emerging market with long-term potential, especially in the regions around Shanghai and north of Hong Kong. It is a pleasure to work with a partner with good experiences of providing products with similar technology to the growing Chinese laboratory market," comments Yvonne Mårtensson, CEO of CellaVision.

The distributor Vastec Medical has sold the first instrument to the Xijing Hospital in Xi'an. The hospital belongs to the Fourth Military Medical University with 2600 hospital beds.

The product registration was issued by the Chinese State Food & Drug Administration, SFDA.

About CellaVision

CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.

The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com .

CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.